ROSE.BA Instituto Rosenbusch S.A.

Healthcare Pharmaceuticals Buenos Aires Exchange
139.50 ARS
Close of Oct 29, 2026
135.50 327.00
Market cap
ARS 5.94B
P/E
0.7x
P/B
0.76x
ROE
60.1%
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ROSE.BA undervalued?

Graham number

The Graham number of Instituto Rosenbusch S.A. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Instituto Rosenbusch S.A. fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (60.1%), above 20%.

ROA 1/1

Return on assets (20.3%) is above the industry median (5.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-146.6%) is below the industry median (-3.6%).

Revenue Growth 2/2

Revenue grew 67.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (34.6%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is negative, against interest expense, below 5x.

PE vs Market 1/1

PE (0.7x) is below the market median (6.7x).

PE vs Industry 1/1

PE (0.7x) is below the industry median (5.8x).

PBV 0/1

Price to book (0.8x) is above the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 0.5, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Instituto Rosenbusch S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Instituto Rosenbusch S.A.

Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and…

Full company profile